ALDX

NASDAQ 已收盘

Aldeyra Therapeutics

0.84 USD
▲+0.12+16.39%
盘后 0.81 -3.57%
2026-11-20
市值
$50.70M
市盈率
—
EPS
-0.32
股息率
—
52 周区间
0.53 – 5.93
成交量
2.51M
Beta
1.29
目标价
6.60
52W 低 0.5352W 高 5.93
价格走势

公司简介

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical ...